We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly and Company announced today that its Board of Directors has declared a dividend for the third quarter of 2006 of 40 cents a share on outstanding common stock.
Azaya Therapeutics Inc. has completed a new round of financing from private investors that company president and CEO Michael T. Dwyer says will enable the San Antonio firm to strengthen its role in the fight against cancer and other diseases.
NexMed, Inc., a developer of innovative pharmaceutical products based on its proprietary, NexACT transdermal drug delivery technology, announced today that Schering AG has terminated its license, supply and distribution agreement for Alprox-TD, NexMed's topical treatment for erectile dysfunction (ED), currently in clinical development.
Eli Lilly's antidepressantProzac does not lower risk of relapse or help anorexia nervosa patients who haverestored their body weight maintain it, according to a study published in the June 14 issue of the Journal of the American Medical Association.
The FDA's own enforcement reports show it to be an agency under increasing pressure to do more with less -- the number of warning letters is dropping even as recalls skyrocket, sources say.